Cargando…
Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma
Cisplatin is one of the most effective chemotherapeutic agents commonly used for several malignancies including oral squamous cell carcinoma (OSCC). Although cisplatin resistance is a major obstacle to effective treatment and is associated with poor prognosis of OSCC patients, the molecular mechanis...
Autores principales: | Suenaga, Naoki, Kuramitsu, Mimi, Komure, Kanae, Kanemaru, Ayumi, Takano, Kanako, Ozeki, Kazuya, Nishimura, Yuka, Yoshida, Ryoji, Nakayama, Hideki, Shinriki, Satoru, Saito, Hideyuki, Jono, Hirofumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829433/ https://www.ncbi.nlm.nih.gov/pubmed/31635163 http://dx.doi.org/10.3390/ijms20205194 |
Ejemplares similares
-
Potential use of EGFR-targeted molecular therapies for tumor suppressor CYLD-negative and poor prognosis oral squamous cell carcinoma with chemoresistance
por: Kanemaru, Ayumi, et al.
Publicado: (2022) -
The Tumour Suppressor CYLD Is Required for Clathrin-Mediated Endocytosis of EGFR and Cetuximab-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma
por: Liu, Rin, et al.
Publicado: (2021) -
Relationship between clinicopathological characteristics and CYLD expression in patients with cholesteatoma
por: Miyake, Shunsuke, et al.
Publicado: (2020) -
Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy
por: Guo, Jianying, et al.
Publicado: (2014) -
Tumor Suppressor CYLD Acts as a Negative Regulator for Non-Typeable Haemophilus influenza-Induced Inflammation in the Middle Ear and Lung of Mice
por: Lim, Jae Hyang, et al.
Publicado: (2007)